Latest news and press releases about Acurx Pharmaceuticals, Inc. (ACXP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections.
Price
| Price | $1.38 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.73 |
| EV / EBITDA | 0.60 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -124.74% |
| Return on Invested Capital | -94.08% |
| Return on Assets | -68.33% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADIL · APRE · APVO · BCDA · BCLI · CELZ · GLTO
Explore sector: Healthcare · Biotechnology
More sections of ACXP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks